Health & Fitness
Tue, November 2, 2010Mon, November 1, 2010Sat, October 30, 2010Fri, October 29, 2010Thu, October 28, 2010Wed, October 27, 2010Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Abiomed Second Quarter Fiscal 2011 Earnings and Conference Call Notification
Published in Health and Fitness on Monday, October 25th 2010 at 6:10 GMT by Market Wire
DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed, Inc ]. (NASDAQ: ABMD) announced today that on Thursday, November 4, 2010, the Company will release financial results for the second quarter of fiscal 2011. The Company will host a conference call to discuss the results on Thursday, November 4, 2010, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via [ http://investor.abiomed.com ] or dial 800.659.1942; the international number is 617.614.2710. The access participant code is 82092317. A replay of this conference call will be available beginning at 11 a.m. ET on November 4, 2010 through 11:59 p.m. ET on November 18, 2010. The replay phone number is 888.286.8010; the international number is 617.801.6888. The replay access code is 72509166.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
